Adrian Howd
Directeur Financier/CFO chez BIVICTRIX THERAPEUTICS PLC
Profil
Adrian G.
Howd is currently the Director at Viamet Pharmaceuticals, Inc., Independent Director at Viamet Pharmaceuticals Corp., Director & Principal at Brandon Point Industries Ltd., Director at Blueberry Therapeutics Ltd., and will be the Chief Financial & Business Officer at BiVictriX Therapeutics Plc starting in 2023.
Previously, he was the Chief Executive Officer at Malin Corp.
Plc from 2015 to 2018.
He also served as a Non-Executive Director at Kymab Ltd., Director at Poseida Therapeutics, Inc., Director at Wavebreak Therapeutics Ltd.
from 2016 to 2018, Non-Executive Director at Immunocore Holdings Plc, and Executive Vice President at Evotec SE.
Dr. Howd started his career as a Research Analyst at ABN AMRO Bank NV (London Branch) in 2008 and later worked as a Research Analyst at Joh.
Berenberg, Gossler & Co. KG (United Kingdom) from 2009 to 2013.
He holds a doctorate degree from the University of London.
Postes actifs de Adrian Howd
| Sociétés | Poste | Début |
|---|---|---|
| BIVICTRIX THERAPEUTICS PLC | Directeur Financier/CFO | 03/10/2023 |
Brandon Point Industries Ltd.
 Brandon Point Industries Ltd. Medical/Nursing ServicesHealth Services Brandon Point Industries Ltd. operates as a life sciences company. It focuses on healthcare. The company was founded in 2014 by George Kelly Martin and John Oliver Thomas Given and is headquartered in Dublin, Ireland. | Directeur/Membre du Conseil | - |
Viamet Pharmaceuticals Corp.
 Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | Directeur/Membre du Conseil | - |
Viamet Pharmaceuticals, Inc.
 Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Directeur/Membre du Conseil | - |
Blueberry Therapeutics Ltd.
 Blueberry Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Blueberry Therapeutics Ltd. engages in the development of innovative medicines. It offers nanomedicine, anti infection and anti microbial, anti inflammatory bowel diseases, acne, dermatitis and wound medicines. The company was founded by John Ridden and Mike Davies and is headquartered in Macclesfield, the United Kingdom. | Directeur/Membre du Conseil | - |
Anciens postes connus de Adrian Howd
| Sociétés | Poste | Fin |
|---|---|---|
Wavebreak Therapeutics Ltd.
 Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom. | Directeur/Membre du Conseil | 28/10/2018 |
| MALIN CORPORATION PLC | Directeur Général | 24/08/2015 |
Joh. Berenberg, Gossler & Co. KG (United Kingdom)
 Joh. Berenberg, Gossler & Co. KG (United Kingdom) Investment Banks/BrokersFinance Joh. Berenberg, Gossler & Co. KG (United Kingdom) (Berenberg-UK) is the Great Britain-based broker/dealer division of Joh. Berenberg, Gossler & Co. KG, a multinational full-service investment bank in Germany. Headquartered in London, Berenberg-UK was founded in 2003 and provides trading and brokerage services to institutional and corporate clients. | Analyst-Equity | 01/06/2013 |
| ABN AMRO Bank NV (London Branch) (Broker) (Old) | Analyst-Equity | 16/04/2008 |
| ░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Adrian Howd
| University of London | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| MALIN CORPORATION PLC | Health Technology |
| EVOTEC SE | Health Technology |
| IMMUNOCORE HOLDINGS PLC | Health Technology |
| POSEIDA THERAPEUTICS, INC. | Health Technology |
| BIVICTRIX THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 8 |
|---|---|
Joh. Berenberg, Gossler & Co. KG (United Kingdom)
Joh. Berenberg, Gossler & Co. KG (United Kingdom) Investment Banks/BrokersFinance Joh. Berenberg, Gossler & Co. KG (United Kingdom) (Berenberg-UK) is the Great Britain-based broker/dealer division of Joh. Berenberg, Gossler & Co. KG, a multinational full-service investment bank in Germany. Headquartered in London, Berenberg-UK was founded in 2003 and provides trading and brokerage services to institutional and corporate clients. | Finance |
| ABN AMRO Bank NV (London Branch) (Broker) (Old) | Finance |
Brandon Point Industries Ltd.
Brandon Point Industries Ltd. Medical/Nursing ServicesHealth Services Brandon Point Industries Ltd. operates as a life sciences company. It focuses on healthcare. The company was founded in 2014 by George Kelly Martin and John Oliver Thomas Given and is headquartered in Dublin, Ireland. | Health Services |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | Health Technology |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Health Technology |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Wavebreak Therapeutics Ltd.
Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Blueberry Therapeutics Ltd.
Blueberry Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Blueberry Therapeutics Ltd. engages in the development of innovative medicines. It offers nanomedicine, anti infection and anti microbial, anti inflammatory bowel diseases, acne, dermatitis and wound medicines. The company was founded by John Ridden and Mike Davies and is headquartered in Macclesfield, the United Kingdom. | Health Technology |
